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Objective: This study aimed to describe and analyze clinical and laboratory characteristics
of  patients with sickle cell anemia treated at the Hemominas Foundation, in Divinópolis,
Brazil. Furthermore, this study aimed to compare the clinical and laboratory outcomes of
the group of patients treated with hydroxyurea with those patients that were not treated
with  hydroxyurea.
Methods: Clinical and laboratorial data were obtained by analyzing medical records of
patients with sickle cell anemia.
Results: Data from the medical records of 50 patients were analyzed. Most of the patients
were female (56%), aged between 20 and 29 years old. Infections, transfusions, cholecys-
tectomy, splenectomy and systemic arterial hypertension were the most common clinical
adverse events of the patients. The most frequent cause of hospitalization was painful crisis.
The  majority of patients had reduced values of hemoglobin and hematocrit (8.55 ± 1.33 g/dL
and  25.7 ± 4.4%, respectively) and increased fetal hemoglobin levels (12 ± 7%). None of the
clinical variables was statistically signiﬁcant on comparing the two groups of patients.
Among hematological variables only hemoglobin and hematocrit levels were statistically
different between patients treated with hydroxyurea and untreated patients (p-value = 0.005
and p-value = 0.001, respectively).
Conclusion: Sickle cell anemia requires treatment and follow-up by a multiprofessional
team. A current therapeutic option is hydroxyurea. This drug reduces complications and
improves laboratorial parameters of patients. In this study, the use of the drug increased
the hemoglobin and hematocrit levels of patients.Please cite this article in press as: Sant’Ana PG, et al. Clinical and labor
Hemoter. 2016. http://dx.doi.org/10.1016/j.bjhh.2016.09.007
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Introduction
Sickle cell anemia (SCA) is an inherited autosomal reces-
sive disease characterized by the presence of homozygous
hemoglobin S (Hb S). It is caused by a single nucleotide muta-
tion that substitutes glutamic acid for valine in the sixth
position of the -globin gene.1 During hypoxic conditions, the
red blood cell becomes sickled and the resulting change in
structure restricts circulation causing obstruction of the blood
ﬂow within the capillaries and early destruction of the cell.2
Clinical manifestations of SCA vary from mild, that is,
almost asymptomatic, to severe forms that are associated
with high mortality rates.3 Clinical manifestations usually
appear after three months of age, when the concentration of
fetal hemoglobin (Hb F) decreases.2 Most systems are liable
to vaso-occlusive processes possibly resulting in multisystem
failure.4–6
A deﬁnitive cure is not currently available for patients with
SCA. Existing therapies are only focused on symptom manage-
ment and do not alter the natural history of the disease. These
therapies are comprised of hydration, prevention of infections,
pain management, proper nutrition and precautions against
adverse weather conditions. Thus, additional therapies are
needed to prevent complications without subjecting patients
to the increased morbidity and mortality associated with
highly aggressive approaches such as hematopoietic stem cell
transplantation (HSCT).
Currently, hydroxyurea (HU) is the only medical modal-
ity with proven efﬁcacy in patients with frequent symptoms
related to SCA.7,8 HU is known to increase Hb F levels, improve
hemoglobin concentrations and mean corpuscular volume,
and reduce the number of reticulocytes. Another favorable
response of treatment is that it does not only reduce the
expression of adhesion molecules, but also decreases the
number of receptor proteins located on endothelial cells.
Therefore, HU decreases vascular adhesion which contributes
by diminishing the number of vaso-occlusive crises.9,10
SCA is an inherited disease with high prevalence and
mortality rate.11 However, the literature is scarce on local
epidemiological studies in Brazil. Hence, this study aims to
analyze the clinical and laboratorial characteristics of patients
with SCA who live in the macro region of Divinópolis, Minas
Gerais treated in the Hemominas Foundation. Furthermore,
this study aims to compare the clinical and laboratorial out-
comes in two groups of patients; those treated with HU to
those that were not treated with HU.
Methods
Study  sample  and  data  collection  procedure
A retrospective study was carried out based on information
extracted from medical records. This study was conducted at
the blood center of the Hemominas Foundation in Divinópolis,
Brazil. All patients from that macro region diagnosed with SCAPlease cite this article in press as: Sant’Ana PG, et al. Clinical and labor
Hemoter. 2016. http://dx.doi.org/10.1016/j.bjhh.2016.09.007
(limited to the homozygous Hb SS genotype) and followed-
up from August 2012 to August 2014 were included. Initially
the planned sample was composed of 57 patients that is, all
cases of SCA at the blood center. However, seven patients 0 1 6;x  x x(x x):xxx–xxx
were excluded from analysis (ﬁve were not followed-up in
the previous two years, one patient died and one patient was
transferred to another blood center).
This study was approved by the Research Ethics Committee
of the Universidade Federal de São João Del Rei, Campus Cen-
tro Oeste Dona Lindu (# 477.473) and by the Research Ethics
Committee of the Hemominas Foundation (# 506.674).
A standardized data extraction form was used to collect
information from patients’ medical records. All data collected
refer to the period of interest (August 2012 to August 2014). The
form contained the following information: age, date of diagno-
sis, date of starting treatment, adherence to the institutional
vaccination protocol (protection against inﬂuenza, meningo-
coccus and pneumococcus), clinical and therapeutic aspects,
and laboratory tests results. The arithmetic mean was calcu-
lated from the last ﬁve laboratory test results within the period
of the trial.
Statistical  analysis
Descriptive statistics are used to report the variables of inter-
est. Categorical variables are reported as absolute and relative
frequencies. Continuous variables are presented as means and
standard deviation or median and interquartile range if the
variable showed non-parametric distribution. Distribution of
the data was tested using the Shapiro–Wilk test. Normally dis-
tributed data were analyzed using the Student’s t-test, whilst
non-parametric data were analyzed using the Mann–Whitney
U test. Pearson’s chi-square test or Fisher’s exact test, as appro-
priate, were used to associate exposure with outcomes. These
analyses were performed using the Statistical Package for
Social Sciences (SPSS Inc., Chicago) version 22 for Windows.
The level of signiﬁcance was set at 5% (p-value <0.05).
Results
Data from the medical records of 50 patients were analyzed.
Females, with a total of 28 (56%), were predominant in the
sample. The age range of the patients was 2–54 years with a
mean of 25.4 ± 12.9 years. When grouped by age, the majority
of the patients were between 20 and 29 years (36%) while the
over 50-year-old age group was the smallest (4%).
The age at diagnosis was reported in 30 patient records,
with 14 (46.7%) patients diagnosed at less than one year of
age (median: 1.0; interquartile range: 0.0–10.5 years) as part of
the Newborn Screening Program in Minas Gerais. Regarding
the number of medical appointments over the previous two
years, 50% of patients had 17 medical appointments or more
(interquartile range: 11–32 consultations).
Clinical  characteristics
Seven patients (14%) underwent splenectomy and 15 patients
(30%) were submitted to cholecystectomy. Nine of the 50
patients had systemic arterial hypertension (18%). Splenicatory proﬁle of patients with sickle cell anemia. Rev Bras Hematol
sequestration was not mentioned in any of the records within
the period studied. The vaccination protocol was described in
31 records with 24 patients (77.4%) adhering to the protocol
established by the Brazilian Health Ministry12; all under
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Table 1 – Clinical characteristics of 50 patients with
sickle cell anemia.
Characteristic n %
Splenectomy 7 14.0
Cholecystectomy 15 30.0
Systemic arterial hypertension 9 18.0
Chronic renal failure 3  6.0
Vaccination protocol (n = 31) 24  77.4
Transfusions 20 40.0
Infections 26 52.0
1 event 17 65.4
≥2 events 9 34.6
Hospitalization 21 42.0
1 event 16 76.2
≥2 events 5 23.8
Priapism (n = 22) 5 22.7
Painful crisis 30 60.0
Others 7 14.0
Referrals
Cardiology 32 64.0
Ophthalmology 38 76.0
Neurology 9 18.0
Other medical specialties 23 46.0
Medications
Hydroxyurea 15 30.0
Vitamins 50 100.0
Analgesic/anti-inﬂammatory 26 52.0
Iron-chelating 11 22.0
Antibiotic 9 18.0
Other 16 32.0
Others: stroke, chronic hypoxemia, acute chest syndrome, bone
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Table 4 shows a descriptive and comparative analysis ofnecrosis, proliferative retinopathy, hematuria.
0-year-old patients adhered to the vaccination protocol.
uring the study period, 20 patients (40%) received blood
ransfusions. Previous infectious events were recorded for 26
atients (52%), with 65.4% having just one infectious episode.
he predominant cause was upper respiratory tract infection
46%), in particular tonsillitis (20% of infections). Twenty-one
atients (42%) were hospitalized mainly for painful crises inPlease cite this article in press as: Sant’Ana PG, et al. Clinical and labor
Hemoter. 2016. http://dx.doi.org/10.1016/j.bjhh.2016.09.007
3.3% of all cases (Table 1).
Regarding common acute events in SCA, priapism was
eported in ﬁve (22.7%) men  and painful crisis in 30 (60%)
Table 2 – Description of hematological variables of 50 patients w
Mean (± standard deviation) 
Hematocrit (%) 25.7 ± 4.4 
Hemoglobin (g/dL) 8.55 ± 1.33 
Leukocytes (cell/mm3) –  
Neutrophil (cell/mm3) – 
Platelets (cell/mm3) 433.418 ± 134.348 
Fetal hemoglobin (%) 12 ± 7 
Serum iron (g/dL) – 
Total iron-binding capacity (mg/dL) – 
Ferritin (ng/mL) – 
Lactate dehydrogenase (UI/L) – 
a Reference values for both genders and age group 2–55 years. 1 6;x x x(x x):xxx–xxx 3
patients (Table 1). Patients were referred for medical special-
ist appointments for a variety of reasons, with the greatest
number of referrals being made to ophthalmology (76%) and
cardiology (64%) services (Table 1).
Pharmacological  therapies
HU was prescribed to 15 patients (30%) at the recommended
initial single dose for adults of 15 mg/kg/day.9,12 Indications
for HU treatment included age older than three, history of
vaso-occlusive crises that required medical support, recur-
rent acute thoracic crises, strokes, recurrent priapism and
severe persistent anemia in the previous 12 months.13 Even
though six patients had a clinical indication for HU treatment,
they did not start treatment. In four cases, this was because
the patients were unable to attend frequent medical appoint-
ments and therefore could not perform periodic laboratorial
tests required as per the protocol.9,12 Of the other two  patients,
one did not receive HU as she was trying to conceive, and one
was a child who did not have an adult to take responsibility for
his treatment. All patients took some vitamins, such as folic
acid, and analgesic/anti-inﬂammatory drugs were widely used
(52% – Table 1).
Laboratorial  characteristics
The descriptive analysis of hematological variables is
shown in Table 2. The hematocrit, total hemoglobin, fetal
hemoglobin, ferritin and lactate dehydrogenase values are
adjusted taking into account the reference values for both
gender and age group (Table 2).
Table 3 compares the incidence of clinical adverse events
between the groups that received HU to those that did not.
There was no statistically signiﬁcant difference for the most
prevalent clinical events. The incidence of the category ‘oth-
ers’, which includes the less common events such as stroke,
acute chest syndrome, chronic hypoxemia, bone necrosis,
proliferative retinopathy and hematuria, was statistically dif-
ferent between the two groups of patients with these events
being more  prevalent in individuals that took HU (Table 3).atory proﬁle of patients with sickle cell anemia. Rev Bras Hematol
hematological variables between the two groups. Hematocrit
and hemoglobin levels were signiﬁcantly different (p-value
0.005 and 0.001, respectively). There were no signiﬁcant dif-
ith sickle cell anemia.
Median (interquartile range 25–75%) Referencea
– 34–49
– 11.5–17.5
10.354 (8.271–13.846) 3500–12,000
4.945 (3.664–6.914) 1500–8000
– 15,000–400,000
– 0
129.3 (86.0–174.0) 35–160
307.5 (276.5–361.0) 228–428
344.0 (152.3–771.0) 10.0–300.0
752.0 (541.9–913.0) 150.0–400.0
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Table 3 – Clinical characteristics of 50 patients with sickle cell anemia treated (on HU) and not treated (off HU)  with
hydroxyurea.
Off HU (n = 35) On HU (n = 15) p-Value
Systemic arterial hypertension 8 (22.9%) 1 (6.7%) 0.247
Splenectomy 4 (11.4%) 3 (20.0%) 0.415
Cholecystectomy 9 (25.7%) 6 (40%) 0.333
Vaccination protocol (n = 31) 18 (78.3%) 6 (75.0%) 1.000
Transfusions 13 (37.1%) 7 (46.7%) 0.529
Infections 19 (54.3%) 7 (46.7%) 0.621
Hospitalization 13 (37.1%) 8 (53.3%) 0.288
Priapism (n = 22) 2 (13.3%) 3 (42.9%) 0.274
Painful crisis 20 (57.1%) 10 (66.7%) 0.529
Others 2 (5.7%) 5 (33.3%) 0.020a
Others: stroke, chronic hypoxemia, acute chest syndrome, bone necrosis, proliferative retinopathy, hematuria.
a Statistically signiﬁcant difference p-value <0.05.
Pearson’s chi-square test or Fisher’s exact test.
Table 4 – Description of hematological variables of 50 patients with sickle cell anemia treated (on HU) and not treated (off
HU) with hydroxyurea.
Off HU (n = 35) On HU (n = 15) p-Value
Hematocrit (%)a 24.6 ± 4.1 28.3 ± 4.1 0.005c
Hemoglobin (g/dL)a 8.15 ± 1.22 9.44 ± 1.14 0.001c
Leukocytes (cell/mm3)b 10,502 (8361–14,776) 9370 (7518–13,600) 0.121
Neutrophil (cell/mm3)b 5118 (4000–7005) 3760 (3016–6689) 0.494
Platelets (cell/mm3)a 431,541 ± 149,615 437,547 ± 96,969 0.869
Fetal hemoglobin (%)a 11 ± 5 14 ± 9 0.212
Serum iron (g/dL)b 127.5 (80.2–171.3) 151.5 (106.7–175.0) 0.438
Total iron-binding capacity (mg/dL)b 313.3 (277.3–368.0) 296.0 (273.0–352.5) 0.398
Ferritin (ng/mL)b 326.0 (114.0–677.6) 528.5 (250.0–1240.2) 0.201
Lactate dehydrogenase (UI/L)b 752.0 (663.5–958.0) 781.5 (438.5–897.7) 0.557
HU: hydroxyurea.
a Mean value ± standard deviation (Student’s t-test).
b Median (interquartile range 25–75%) (Mann–Whitney U test).
c Statistically signiﬁcant difference p-value <0.05.
ferences between the groups in respect to the other variables
(Table 4).
Discussion
According to the results of this study, most patients were
female, predominantly aged between 20 and 29 years of age
and had been diagnosed at around the age of one. Similar
ﬁndings were reported in other studies from Brazil; the major-
ity of cases were women and were aged between 18 and 30
years.14 One study conducted in Paraná showed a predomi-
nance of females with a gender ratio of 2:1 in children with
SCA.15 In a national study of patients with sickle cell disease,
the average age at diagnosis was 8.4 years.14 In this study,
the median age at diagnosis was one year, which meets the
current national expectations set by the National Program of
Neonatal Screening by the Brazilian Health Ministry in 2001.
Regarding the clinical characteristics, the rate of chole-
cystectomies was high (30%) in this sample compared toPlease cite this article in press as: Sant’Ana PG, et al. Clinical and labor
Hemoter. 2016. http://dx.doi.org/10.1016/j.bjhh.2016.09.007
the general population. This number is due to the greater
risk of these individuals developing gallstones, which is in
accordance with what has been previously reported in the
literature, estimated at 50%.16,17 Splenectomy was anotherprocedure commonly performed in the patients of the cur-
rent study (14%). This surgical procedure is aimed at reducing
deaths from recurrent episodes of acute splenic sequestration;
it sometimes improves nutritional status and hematologi-
cal levels related to chronic hypersplenism. According to the
literature, the prevalence of acute splenic sequestration is
estimated at around 7.5–30%.18,19 Although not all patients
investigated in this study were referred for surgery, the rate
of splenectomy in this study was within the expected range.
Nine of the 50 patients studied had systemic arterial
hypertension (18%). Perhaps this ﬁnding is due to the high
prevalence of this disease among Brazilian adults in general
(20%).20 Although experimental and clinical studies report
the impact of nitric oxide depletion on the pathogenesis of
pulmonary hypertension in SCA, no studies correlate arterial
hypertension to SCA.21
There was a high rate of infections in this sample (52%).
These ﬁndings can be explained by the fact that autosplenec-
tomy generally occurs before the patients are 5 years old.
Autosplenectomy is caused by splenic infarcts culminatingatory proﬁle of patients with sickle cell anemia. Rev Bras Hematol
in atrophy and ﬁbrosis of the spleen. Even prior to this pro-
cess, splenic lesions can lead to functional asplenia, which can
become permanent when the patient has reached 6–8 years of
age, making them liable to infections. In fact, infections have
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een reported as one of the most frequent complications in
ndividuals with SCA.2
Most patients (77.4%) were submitted to the vaccination
rotocol. The literature explains this ﬁnding by the early diag-
osis of SCA and screening programs, which enables the
ollow-up of children with SCA with early antibiotic prophy-
axis and immunization against encapsulated bacteria.2
Painful crises in 42% of patients were the commonest rea-
on for hospitalization during the two years of this study. Pain,
he most impacting presentation of the disease, is the result of
bstruction of the microcirculation caused by sickled red blood
ells. It frequently happens without prodromes and affects the
atients’ quality of life.22
Ophthalmology and cardiology diseases were the two
ost common motives for patient referrals (76% and 64%
f patients, respectively). Previous studies have shown the
mportance of ophthalmic evaluations in patients with
CA in order to prevent advanced eye disorders.23 Car-
iomegaly, myocardial ischemia, biventricular dysfunction
nd pulmonary hypertension are the most frequent clinical
omplications related to cardiovascular changes in sickle cell
isease. They may occur due to chronic hemolytic anemia, or
econdary to pulmonary disorders or to iron overload from
lood transfusions.24
The literature shows favorable outcomes with the use of
U, such as increases in hemoglobin, mean corpuscular vol-
me,  number of leukocytes, neutrophils and platelets.25,26
n comparing the two groups, increases in hemoglobin and
ematocrit values were statistically signiﬁcant in this study.
There were no signiﬁcant differences between the patients
eceiving HU compared to those who  were not being treated
ith HU with regard to painful crises, infections, hospital-
zations and number of transfusions, unlike other studies
hat indicated an improvement in these clinical outcomes.19
owever, it is important to highlight some points that could
ontribute to this difference, particularly in relation to clinical
nd laboratory outcomes. By deﬁnition, patients who required
U were at a more  severe stage of the disease as they met  the
linical criteria for the use of HU. In contrast, the group that
id not receive HU was comprised of clinically heterogeneous
atients. Perhaps the patients who did not use the medication
resented with a milder form of the disease and therefore, did
ot meet the criteria for using the medication. Despite this,
ix patients had clinical indications to start treatment with HU
ut did not as they did not attend medical appointments fre-
uently enough as demanded by the protocol. Thus, the group
ot receiving the medication was comprised of patients with
aried clinical presentations. A comparison between a group
ith clinical indications that is taking HU and a group with-
ut clinical indications who did not take HU would provide
 more  accurate idea of the beneﬁts of the drug. However,
ethodological issues such as the total number of patients
nd the cross-sectional design of the study preclude deﬁnitive
onclusions.
This study has some limitations that need to be acknowl-
dged. The population investigated was very speciﬁc and wasPlease cite this article in press as: Sant’Ana PG, et al. Clinical and labor
Hemoter. 2016. http://dx.doi.org/10.1016/j.bjhh.2016.09.007
ot randomly selected. Therefore, this sample may not be rep-
esentative of the population, affecting the generalization of
he results. Furthermore, the heterogeneity of patients, and
he relatively small sample size presented a challenge since
1 1 6;x x x(x x):xxx–xxx 5
it was not possible to perform sub-group analyses. Future
studies should investigate a larger sample to overcome this
limitation. Additionally, the patients’ medical records could
not be linked to records from other healthcare facilities, such
as hospitals. In summary, more  studies are needed, particu-
larly those that focus on grouping patients with similar clinical
presentations prior to comparison.
Conclusion
Sickle cell anemia requires treatment and follow-up by
a multiprofessional team. A current therapeutic option is
hydroxyurea. This drug reduces complications and improves
laboratorial parameters of patients. In this study, the use of
the drug increased the hemoglobin and hematocrit levels of
patients.
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